RAIA DROGASIL S.A. INSTITUTIONAL PRESENTATION
3Q22
Disclaimer.
The material that follows is a presentation of general background information about Raia Drogasil S.A. (the "Company") as of the date of the presentation. It is information in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential investors. This presentation is strictly confidential and may not be disclosed to any other person. No representation or warranty, express or implied, is made concerning, and no reliance should be placed on, the accuracy, fairness, or completeness of the information presented herein.
This presentation contains statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Exchange Act of 1934. Such forward-looking statements are only predictions and are not guarantees of future performance. Investors are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the operations and business environments of the Company that may cause the actual results of the companies to be materially different from any future results expressed or implied in such forward-looking statements.
Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonable based on information currently available to the Company's management, the Company cannot guarantee future results or events. The Company expressly disclaims a duty to update any of the forward looking-statements.
Our securities have not been and will not be registered under the Securities Act or under any state securities laws in the United States, and are being offered under exemptions from registration under the Securities Act. Securities may not be offered or sold in the United States unless they are registered or exempt from registration under the Securities Act. Any offering to be made in the United States will be made by means of an offering circular that may be obtained from the agents.
This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.
2
Leading the consolidation of pharma retailing in Brazil.
Our Purpose: | +200 years | #1 pharmacy |
of combined history of Raia and | chain in | |
Drogasil, merged in 2011 | Brazil |
Taking close care of people's health and well-beingduring all times of their lives.
... For over 100 years, we have been "providing the best experience to turn casual customers into
loyal customers" ...
2,620 | 260 |
pharmacies across every | new pharmacies in 2022 and |
Brazilian state | 1,040 between 2022-25 (guidance) |
46 million | NPS 90 |
unique active | pharmacy net |
customers (3Q22 LTM) | promoter score |
319 million | 500 million |
tickets | digital sessions |
(3Q22 LTM) | (annualized) |
R$ 29.5 billion | 15.0% |
gross revenue (3Q22 LTM) | market share |
+20% Y/Y growth | in the 3Q22 |
R$ 2.1 billion | AAA(bra) |
EBITDA (3Q22 LTM) | rating by |
+18% Y/Y growth | Fitch |
3
Fragmented market with secular demand growth due to the ageing of the population.
The Brazilian pharmaceutical market maintains
an accelerated long-term growth
(R$ billions. Source: IQVIA.)
144
126
113
103
96
85
75
66
58
50
43
36
30
11 12 13 15 17 19 21 21 25
2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
Brazilian population over 65 years of age
(Millions. Source: IBGE.)
40.1 | ||||
30.0 | ||||
20.0 | ||||
9.7 | 13.3 | |||
2000 | 2010 | 2020 | 2030 | 2040 |
Fragmented market: opportunity for consolidation
(Market share. Source: IQVIA.)
9.2% | 9.8% | 10.8% | 11.4% | 11.8% | 13.4% | 13.5% | 14.1% |
18.6% | 17.5% | 16.3% | 16.4% | 16.3% | 16.0% | 15.2% | 15.2% |
22.5% | 24.7% | 24.9% | 23.9% | 23.3% | 22.3% | 21.8% | 21.0% |
17.2% | 15.9% | 16.7% | 17.6% | 18.4% | 19.1% | 20.2% | 22.0% |
32.5% | 32.1% | 31.3% | 30.7% | 30.3% | 29.1% | 29.2% | 27.6% |
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |||
Independents | Assoc./Franch. | Other Chains | Abrafarma #2 to 5 | RD | ||||||
4
RD completed 10 years of history, with strong growth and value creation based on a traditional retail strategy.
776 864
Pharmacies
(Store count)
3x
2,490
2,299
2,070
1,822
1,607
1,417
1,232
1,091
967
Employees
(Thousands)
3x
50.6
44.6
41.5
36.5
32.3
28.9
26.5
23.7
20.121.5
17.2
4.7 5.6
Gross revenue
(R$ billions)
5x
25.6
21.2
18.4
15.5
13.9
11.8
9.4
7.8
6.5
Adjusted EBITDA
(R$ millions)
7x
1,807
1,429
1,344
1,195
1,130
988
744
544
326 357
272
'11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 | '11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 | '11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 | '11 | '12 | '13 | '14 | '15 | '16 | '17 | '18 | '19 | '20 | '21 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Raia Drogasil SA published this content on 10 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2023 12:21:07 UTC.
